Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
An Open Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
NCT Number:
NCT03767348
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Other Skin, Lung, Melanoma, Skin
Study Objectives:
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Study Documents
(MUSC NetID required for document access)